Trial Profile
A Study Evaluating Efficacy And Safety Of Switch From Darunavir/Ritonavir (DRV/r) to Darunavir/Cobicistat (DRV/COBI) For The Treatment Of Patients With HIV-Infections.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 31 Dec 2016
Price :
$35
*
At a glance
- Drugs Cobicistat/darunavir (Primary)
- Indications HIV infections
- Focus Therapeutic Use
- 31 Dec 2016 New trial record